Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InSite Vision has submitted ISV-101 investigational new drug (IND) application with the US Food and Drug Administration (FDA) as a treatment for treat dry eye disease.
Subscribe to our email newsletter
The company expects to initiate a Phase 1/2 clinical trial to investigate the safety and efficacy of the drug, in 2011.
ISV-101 combines a low dose of the non-steroidal anti-inflammatory (NSAID) bromfenac (Bromday/Xibrom marketed by ISTA Pharmaceuticals) with InSite Vision‘s proprietary DuraSite technology.
InSite Vision said that the initial data from clinical studies evaluating the combination of DuraSite with a higher dose of bromfenac have demonstrated a favorable safety profile.
InSite Vision CEO Timothy Ruane said that with patent protection extending into 2029, they believe ISV-101 can be well positioned to compete in the expanding $500m US dry eye market.